This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Cincinnati Children's Hospital Medical Center, Kurome Therapeutics, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2026.
Company Filing History:
1 out of 429 
1 out of 2 
1 out of 3,688 
Years Active: 2026
Title: The Innovative Contributions of Patrick Joseph Sutter
Introduction
Patrick Joseph Sutter is a notable inventor based in Waco, Texas. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit IRAK and FLT3. His work has the potential to impact the treatment of various diseases, including hematopoietic cancers and acute myeloid leukemia.
Latest Patents
Sutter holds a patent for "Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof." This patent includes inventive compounds and pharmaceutical compositions that inhibit IRAK and/or FLT3. These compounds can be utilized for treating diseases such as myelodysplastic syndromes and acute myeloid leukemia. Additionally, the patent outlines methods for administering these compounds in combination with other cancer therapies.
Career Highlights
Throughout his career, Patrick Joseph Sutter has worked with prestigious organizations, including Cincinnati Children's Hospital Medical Center and the United States Department of Health and Human Services. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Sutter has collaborated with notable colleagues, including Craig J. Thomas and Jan Susan Rosenbaum. These partnerships have further enhanced his research and development efforts in the pharmaceutical industry.
Conclusion
Patrick Joseph Sutter's innovative work in developing IRAK and FLT3 inhibiting compounds showcases his dedication to advancing medical treatments. His contributions are poised to make a significant impact on the treatment of serious diseases.